Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link ).Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26...
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the...
Strawberry Fields REIT Announces Year-End 2025 Earnings Release, Conference Call and Webcast SOUTH BEND, Ind., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) announced today that it will report its year-end 2025 financial results on February 19, 2026, after the close of market. On February 20, 2026 at 11:00 a.m. Eastern Time, the Company’s management team will be holding a conference call/webcast to discuss the 2025 year-end results and invites current and prospective investors to join. To access the conference call, please pre-regis...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Texas Capital Bancshares, Inc. Announces Fourth Quarter and Full Year 2025 Results Fourth quarter 2025 net income available to common stockholders of $96.3 million, up 44% year-over-yearReaching record-levels, Book Value and Tangible Book Value(4) per share both increased 13% year-over-yearCapital ratios continue to be strong, achieving 12.1% CET1 and 16.1% Total Capital DALLAS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- “Consecutive strong quarters to close 2025 validate our multi-year transformation strategy and demonstrate the resilience of our business model in a complex market environment,” ...
Texas Capital Bancshares, Inc. Announces Date for Full Year and Q4 2025 Operating Results DALLAS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the full year and fourth quarter of 2025 before market on Thursday, January 22, 2026. Executive management will host a conference call and webcast to discuss full year and fourth quarter 2025 operating results on Thursday, January 22, 2026, at 9:00 a.m. EDT. Participants may pre-register for the call by visit...
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE...
Strawberry Fields REIT Inc. (NYSE American: STRW) CEO Highlights Discipline, Scale, and Steady Returns at NobleCon21 Chairman and CEO Moishe Gubin used his NobleCon21 presentation to outline Strawberry Fields REIT’s disciplined expansion strategy and long-term approach to healthcare real estate.The company now holds long-term leasehold interests in 142 healthcare facilities with more than 15,500 licensed beds across 10 states.Gubin emphasized a conservative acquisition philosophy, with each property evaluated from an operator’s perspective despite the company’s role as a self-administered R...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.